ProCE Banner Activity

Phase III TULIP: vic-Trastuzumab Duocarmazine vs Physician’s Choice Treatment in Previously Treated HER2+ Advanced Breast Cancer

Slideset Download
Conference Coverage
vic-Trastuzumab duocarmazine, a novel antibody–drug conjugate, improved median PFS vs physician’s choice therapy in pretreated HER2+ locally advanced or metastatic breast cancer.

Released: September 28, 2021

Expiration: September 27, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc